Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death

被引：56

作者：

Hare, CB

Vu, MP

Grunfeld, C

Lampiris, HW

机构：

[1] Univ Calif San Francisco, Div Infect Dis, Posit Hlth Program, San Francisco, CA 94110 USA

[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA

[3] San Francisco Vet Adm Med Ctr, Serv Pharm, San Francisco, CA USA

[4] San Francisco Vet Adm Med Ctr, Metab Sect, San Francisco, CA USA

[5] San Francisco Vet Adm Med Ctr, Div Infect Dis, San Francisco, CA USA

来源：

CLINICAL INFECTIOUS DISEASES | 2002年 / 35卷 / 10期

关键词：

D O I：

10.1086/344179

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.

引用

页码：E111 / E112

页数：2

共 14 条

[1] Pharmacokinetic enhancement of protease inhibitors [J].

Acosta, EP .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 :S11-S18

[2] Protease inhibitors in patients with HIV disease - Clinically important pharmacokinetic considerations [J].

Barry, M ;

Gibbons, S ;

Back, D ;

Mulcahy, F .

CLINICAL PHARMACOKINETICS, 1997, 32 (03) :194-209

[3]

Dubé MP, 2000, CLIN INFECT DIS, V31, P1216

[4] Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study [J].

Fellay, J ;

Marzolini, C ;

Meaden, ER ;

Back, DJ ;

Buclin, T ;

Chave, JP ;

Decosterd, LA ;

Furrer, H ;

Opravil, M ;

Pantaleo, G ;

Retelska, D ;

Ruiz, L ;

Schinkel, AH ;

Vernazza, P ;

Eap, CB ;

Telenti, A .

LANCET, 2002, 359 (9300) :30-36

[5] Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 [J].

Fichtenbaum, CJ ;

Gerber, JG ;

Rosenkranz, SL ;

Segal, Y ;

Aberg, JA ;

Blaschke, T ;

Alston, B ;

Fang, F ;

Kosel, B ;

Aweeka, F .

AIDS, 2002, 16 (04) :569-577

[6] Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin [J].

Hsyu, PH ;

Schultz-Smith, MD ;

Lillibridge, JH ;

Lewis, RH ;

Kerr, BM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) :3445-3450

[7]

MARTIN CM, 2000, 40 INT C ANT AG CHEM

[8] FDA adverse event reports on statin-associated rhabdomyolysis [J].

Omar, MA ;

Wilson, JP .

ANNALS OF PHARMACOTHERAPY, 2002, 36 (02) :288-295

[9] Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection [J].

Penzak, SR ;

Chuck, SK ;

Stajich, GV .

PHARMACOTHERAPY, 2000, 20 (09) :1066-1071

[10] Simvastatin and lovastatin, but not pravastatin, interact with MDR1 [J].

Sakaeda, T ;

Takara, K ;

Kakumoto, M ;

Ohmoto, N ;

Nakamura, T ;

Iwaki, K ;

Tanigawara, Y ;

Okumura, K .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (03) :419-423

← 1 2 →